• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Luna Innovations Enters into Definitive Agreement to be Acquired by TJC

    6/26/26 8:00:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $LUNA alert in real time by email

    Stockholders to receive $1.39 per share in cash

    Represents a premium of approximately 26% to Luna’s 60-day volume-weighted average trading price

    Transaction expected to close in the second half of 2026, subject to stockholder approval and other customary closing conditions

    Luna Innovations Incorporated (OTC:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber optic-based technology, today announced that it has signed a definitive agreement (the "Merger Agreement") with Ascend Parent, LLC ("Parent"), a Delaware limited liability company affiliated with TJC, L.P. ("TJC"), pursuant to which TJC will acquire 100% of Luna (the "Transaction").

    Under the terms of the Merger Agreement, each outstanding share of the Company’s common stock will be converted into the right to receive $1.39 in cash, without interest (the "Merger Consideration").

    "This agreement enhances Luna’s ability to achieve our mission of solving our customers’ most urgent problems using our mastery of light. The transaction would close our chapter as a publicly traded company and provide access to the industrial and financial experience and foundation of the TJC platform. We believe this combination strengthens our commitment to our loyal customers and provides greater opportunities for our employees and suppliers," said Kevin Ilcisin, President and Chief Executive Officer of Luna.

    Erik Fagan, Partner and Head of Industrial Technology at TJC, said, "Luna manufactures specialized, highly engineered, and mission-critical products for optical applications across a wide spectrum of industrial technology end markets. We have structured our all-equity transaction to support the growth and investment needed to meet customers’ growing demand and to continue delivering innovative products that improve their performance and efficiency."

    Robbie Redmond, Partner at TJC, added, "We are excited to partner with Kevin and the entire Luna management team. Luna’s dedicated employees have built a remarkable foundation in fiber optic-based measurement technology, and we look forward to investing behind their leadership—supporting the team as they scale the business, advance their product portfolio, and deliver even greater value to the customers who depend on Luna."

    Transaction Overview

    The Transaction is subject to approval by the holders of a majority of the voting power represented by the issued and outstanding shares of the Company’s common stock entitled to vote thereon. The Company will hold a special meeting of stockholders to vote on the adoption of the Merger Agreement and will mail a proxy statement and related materials to stockholders of record in advance of the meeting. The Transaction is also subject to the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions. The Merger is expected to close in the second half of 2026, subject to the satisfaction or waiver of these conditions.

    Meaningful Premium to Market

    Under the Merger Agreement, Shareholders will receive $1.39 Cash Consideration per Share (on closing). The Merger Consideration represents a premium of approximately 26% over the 60-day volume-weighted average trading price of the Company’s common stock and a 29% premium over the volume-weighted average trading price of the Company’s common stock since announcing its move to the OTC Expert Market on January 6, 2025.

    Significant Shareholder Support

    White Hat Capital Partners LP and its affiliates (together, representing approximately 25% voting power) have entered into voting support agreements in favor of the Transaction, subject to customary exceptions.

    Business Operations and Stakeholder Continuity

    Luna’s business operations will continue in its ordinary course during the period between signing and the closing of the Transaction. The Company’s existing relationships with customers, vendors, suppliers and other business partners are expected to continue without disruption. Following the closing, Luna will continue to operate its business as a wholly owned subsidiary of Parent.

    Background for Stockholders

    As the Company’s stockholders are aware, the Company’s common stock was delisted from the Nasdaq Capital Market on February 6, 2025 and has since traded on the OTC Expert Market under the symbol "LUNA." Following its delisting, the Company filed a Form 15 with the SEC to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934 and suspend its reporting obligations under Sections 13 and 15(d) of the Exchange Act. The Company has not filed periodic financial reports with the SEC since that time.

    In connection with the Transaction, the Company will provide stockholders with a proxy statement containing detailed information about the Company’s financial condition, the Transaction, the background of the transaction, and the factors considered by the Board of Directors in approving the Transaction. The proxy statement will include financial statements for the fiscal years ended December 31, 2025 and 2024 and the interim period ended March 31, 2026. Stockholders are urged to read the proxy statement and other relevant materials carefully and in their entirety when they become available.

    Advisors

    Evercore Group L.L.C. is serving as financial advisor and King & Spalding LLP is serving as legal counsel to Luna. Guggenheim Securities, LLC is serving as financial advisor and Kirkland & Ellis LLP is serving as legal counsel to TJC.

    About Luna Innovations Incorporated

    Luna Innovations Incorporated is a global leader in advanced fiber optic-based technology. Luna’s unique capabilities in high-performance fiber optic test, measurement, and sensing solutions serve customers in the data center, semiconductor, aerospace, defense, telecommunications, energy, automotive, scientific research and infrastructure sectors. Headquartered in Roanoke, Virginia, Luna operates facilities across North America and internationally. For more information, visit www.lunainc.com.

    About TJC, L.P.

    TJC LP, formerly known as The Jordan Company, has worked for more than 40 years with CEOs, founders and entrepreneurs across a range of industries including Diversified Industrials, Industrial Technology, Logistics & Business Services, Digital & Power Infrastructure, Healthcare and Consumer. With $31.9 billion of assets under management as of March 31, 2026, TJC is managed by a senior leadership team that has invested together for over 24 years on over 90 investments. TJC has offices in New York, Chicago, Miami and Stamford. For more information, please visit www.tjclp.com.

    Forward-Looking Statements

    The statements in this release that are not historical facts constitute "forward-looking statements." These statements include, but are not limited to, statements regarding the proposed Transaction, the expected timing of closing of the Transaction, the anticipated benefits of the Transaction, the anticipated continuation of the Company’s business operations, and the expected treatment of existing business relationships. Management cautions the reader that these forward-looking statements are only predictions and are subject to a number of both known and unknown risks and uncertainties, and actual results, performance, and/or achievements of the Company may differ materially from the future results, performance, and/or achievements expressed or implied by these forward-looking statements because of a number of factors. These risks and uncertainties include, but are not limited to: the possibility that the Transaction will not be completed in a timely manner or at all; the failure to obtain required stockholder approval; the failure to satisfy other closing conditions; and the occurrence of events that may give rise to a right of one or both parties to terminate the Merger Agreement. The statements made in this release are based on information available to Luna as of the date of this release and Luna undertakes no obligation to update any of the forward-looking statements after the date of this release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260625893697/en/

    Investor Contact:

    Kevin Ilcisin

    Luna Innovations Incorporated

    Email: IR@lunainc.com

    Get the next $LUNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LUNA

    DatePrice TargetRatingAnalyst
    7/28/2023$12.50Buy
    Stifel
    5/22/2023$10.00Buy
    Needham
    3/15/2023$8.00Outperform → Market Perform
    Northland Capital
    5/23/2022$8.00Market Perform → Outperform
    Northland Capital
    More analyst ratings

    $LUNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Luna Innovations Enters into Definitive Agreement to be Acquired by TJC

    Stockholders to receive $1.39 per share in cash Represents a premium of approximately 26% to Luna’s 60-day volume-weighted average trading price Transaction expected to close in the second half of 2026, subject to stockholder approval and other customary closing conditions Luna Innovations Incorporated (OTC:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber optic-based technology, today announced that it has signed a definitive agreement (the "Merger Agreement") with Ascend Parent, LLC ("Parent"), a Delaware limited liability company affiliated with TJC, L.P. ("TJC"), pursuant to which TJC will acquire 100% of Luna (the "Transaction"). Under the terms of the Merger A

    6/26/26 8:00:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations Incorporated - Notice of Pendency and Proposed Settlement of Stockholder Derivative Action

    Luna Innovations Incorporated (OTC:LUNA), a global leader in advanced fiber-optic technology, today announced a Notice of Pendency and Proposed Settlement of Stockholder Derivative Action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216383469/en/View source version on businesswire.com: https://www.businesswire.com/news/home/20260216383469/en/ Investor Contact: Ryan Stewart, General Counsel Luna Innovations Incorporated Phone: (540) 769-8400 Email: stewartr@lunainc.com

    2/16/26 8:00:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations Reports Q3 2025 Results Including Continued Bookings Growth and Margin Expansion

    Luna Innovations Incorporated (OTC:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber-optic technology, today announced preliminary unaudited financial results for the third quarter ended September 30, 2025. The Company reported continued growth in bookings, revenue, and positive cash generation. "Our third quarter performance reflects disciplined execution and sustained attractiveness of our core markets," said Kevin Ilcisin, President and Chief Executive Officer of Luna. "Both our Optical Communications and Sensing businesses delivered growth while we continued to improve margins and strengthen liquidity." Financial Highlights for the Third Quarter Ended September 30, 20

    11/4/25 8:00:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Luna Innovations with a new price target

    Stifel initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $12.50

    7/28/23 7:35:40 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Needham initiated coverage on Luna Innovations with a new price target

    Needham initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $10.00

    5/22/23 7:57:49 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations downgraded by Northland Capital with a new price target

    Northland Capital downgraded Luna Innovations from Outperform to Market Perform and set a new price target of $8.00

    3/15/23 8:52:49 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Financials

    Live finance-specific insights

    View All

    Luna Innovations Reports Q3 2025 Results Including Continued Bookings Growth and Margin Expansion

    Luna Innovations Incorporated (OTC:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber-optic technology, today announced preliminary unaudited financial results for the third quarter ended September 30, 2025. The Company reported continued growth in bookings, revenue, and positive cash generation. "Our third quarter performance reflects disciplined execution and sustained attractiveness of our core markets," said Kevin Ilcisin, President and Chief Executive Officer of Luna. "Both our Optical Communications and Sensing businesses delivered growth while we continued to improve margins and strengthen liquidity." Financial Highlights for the Third Quarter Ended September 30, 20

    11/4/25 8:00:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations to Delay Release of Fourth Quarter and Full Year 2023 Financial Results

    Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced it will delay the release of its fourth quarter and fiscal year 2023 financial results and the subsequent conference call. A Special Committee of the Company's Board of Directors is conducting an independent review, with the assistance of external legal and financial advisors, of certain transactions for which revenue was recognized in the second and third quarters of 2023 that did not qualify for revenue recognition under U.S. generally accepted accounting principles. The Special Committee is examining the circumstances surrounding these issues and is eva

    3/12/24 4:20:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Announces $50 Million Strategic Investment from White Hat Capital Partners

    Investment Proceeds Used to Fund Silixa Acquisition and Enhance Luna's Financial Flexibility to Pursue Strategic Growth Initiatives Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced a $50 million investment by White Hat Capital Partners ("White Hat"), an investment firm focused on sustainable value creation in technology companies serving mission-critical applications. Proceeds from this strategic investment were partially used to fund the acquisition of Silixa, also announced today, and related transaction costs in the aggregate amount of approximately $25 million. Remaining proceeds were used to repay the Company's o

    12/21/23 9:34:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Leadership Updates

    Live Leadership Updates

    View All

    Luna Innovations Announces Baker Tilly as New Independent Auditor

    Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

    4/2/25 8:52:00 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Announces Resignation of Pamela Coe

    Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, Pamela Coe, a member of the Board of Directors (the "Board"), will be retiring from the Luna board effective today. Ms. Coe was elected to the Board in May 2021 for a three-year term. "We are very grateful for Pam's notable contributions and leadership throughout her time on the Board," said Barry Phelps, Chairman of the Board of the Company. "Her expertise, focus and commitment have been instrumental in guiding Luna. We wish Pam all the best in her future endeavors." About Luna Luna Innovations Incorporated (www.lunainc.com) is a leader in optic

    12/27/24 4:40:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations Announces CFO Transition: Names William Phelan as Chief Financial Officer and Chief Accounting Officer

    Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the appointment of William L. Phelan as its new Chief Financial Officer and Chief Accounting Officer, effective immediately. Mr. Phelan succeeds John Roiko, who joined Luna out of retirement in May 2024 and played a key role in establishing a resilient foundation for Luna's future growth. Following the appointment of Mr. Phelan, Mr. Roiko will shift to a consulting role to support the ongoing restatement process. "We are delighted to welcome Bill to the Luna leadership team," said Kevin Ilcisin, President and CEO of Luna. "Bill's highly relevant experience will be instrume

    10/16/24 4:30:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Luna Innovations Incorporated

    SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

    11/14/24 12:32:28 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by Luna Innovations Incorporated

    SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

    11/14/24 8:39:20 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Luna Innovations Incorporated

    SC 13G/A - LUNA INNOVATIONS INC (0001239819) (Subject)

    11/12/24 4:02:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    SEC Filings

    View All

    Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

    1/27/25 10:26:44 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated

    SCHEDULE 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

    1/14/25 1:56:29 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

    1/6/25 8:30:40 AM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $LUNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Spiegel Gary converted options into 10,672 shares, increasing direct ownership by 15% to 81,625 units (SEC Form 4)

    4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

    1/3/25 4:44:17 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Anderson N Leigh converted options into 19,869 shares, increasing direct ownership by 122% to 36,102 units (SEC Form 4)

    4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

    1/3/25 4:43:48 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Coe Pamela L converted options into 13,372 units of Common Stock (SEC Form 4)

    4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

    12/26/24 5:52:51 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care